By Specialty Pharmacy Continuum Staff
The FDA approved idecabtagene vicleucel (ide-cel) (Abecma, Bristol Myers Squibb/bluebird bio) to treat adults with relapsed or refractory multiple myeloma who have received at least four different previous therapies.
Ide-cel—a B-cell maturation antigen (BCMA)-directed, genetically modified, autologous T-cell immunotherapy—is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma.
Nikhil C. Munshi, MD, lead